Ipilimumab
Ipilimumab is a monoclonal antibody used in cancer immunotherapy. It works by activating the immune system to recognize and attack cancer cells. It is commonly used in the treatment of advanced melanoma and certain other cancers.- Advanced or metastatic melanoma - Renal cell carcinoma (in combination with nivolumab) - Other cancers as determined by oncologists
- Usually administered as an intravenous infusion - Standard dosage: 3 mg/kg every 3 weeks for 4 doses (melanoma) - Dosage may vary depending on the type of cancer and combination therapy - Must be administered under medical supervision
- Known hypersensitivity to Ipilimumab or any component of the formulation - Active autoimmune disease - Severe infections
- Monitor for immune-related adverse reactions (e.g., colitis, hepatitis, dermatitis, endocrinopathies) - Use with caution in patients with pre-existing autoimmune disorders - Ensure patients are up to date with vaccinations prior to therapy - Pregnancy and breastfeeding: Only if clearly needed and after consulting a physician
- Fatigue, diarrhea, and rash - Nausea, vomiting, and fever - Immune-related side effects such as inflammation of intestines, liver, lungs, or endocrine glands - Rare but severe: Infusion reactions, severe autoimmune reactions
- Immunosuppressive agents may reduce the effectiveness of Ipilimumab - Concurrent use with other immune checkpoint inhibitors may increase risk of severe immune-related adverse events - Live vaccines should be avoided during treatment
